Related Experiment Video
Updated: Jun 19, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Angiogenesis in rheumatoid arthritis.
Zoltán Szekanecz1, Timea Besenyei, György Paragh
1Department of Rheumatology, Institute of Medicine, University of Debrecen Medical and Health Sciences Center, Debrecen, H-4032, Hungary. szekanecz.zoltan@med.unideb.hu
Autoimmunity
|October 30, 2009
Summary
Rheumatoid arthritis (RA) involves new blood vessel formation (angiogenesis) driven by factors like VEGF and HIFs. Targeting these mediators and using compounds like thalidomide may help manage RA by inhibiting synovial angiogenesis.
Area of Science:
- * Biomedical science
- * Rheumatology
Background:
- * Angiogenesis, the formation of new blood vessels, is crucial in physiological and pathological processes.
- * The perpetuation of angiogenesis is strongly associated with rheumatoid arthritis (RA).
Purpose of the Study:
- * To review the role of angiogenic mediators in rheumatoid arthritis.
- * To explore potential therapeutic targets and compounds for managing RA-associated synovial angiogenesis.
Main Methods:
- * Literature review of soluble and cell-bound factors involved in angiogenesis.
- * Analysis of established and potential therapeutic inhibitors of angiogenic pathways.
- * Examination of naturally produced or synthetic compounds for RA management.
Main Results:
- * Key angiogenic mediators in RA include vascular endothelial growth factor (VEGF), hypoxia-inducible factors (HIFs), pro-inflammatory cytokines, and chemokines.
- * Potential therapeutic targets to inhibit synovial angiogenesis include VEGF, HIF-1, tumor necrosis factor-alpha, and alpha(V)beta(3) integrin.
- * Several compounds like angiostatin, endostatin, paclitaxel, and thalidomide show promise in RA management.
Conclusions:
- * Angiogenesis is a critical component of rheumatoid arthritis pathogenesis.
- * Targeting specific angiogenic mediators offers a promising strategy for RA treatment.
- * Pharmacological interventions, including novel compounds, may effectively attenuate synovial angiogenesis in RA.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...